We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Endomag received premarket approval from the FDA for its non-radioactive, dual-tracer for mapping out lymph nodes in breast cancer patients undergoing mastectomy, a week after raising $10 million in series C funding.